Rebuilding the barrier
How Leuvas is targeting and resealing the BBB in epilepsy
Leuvas Therapeutics Inc., Mountain View, Calif.
Approved therapies for epilepsy control seizures by suppressing firing, but the drugs are ineffective in about one third of patients, produce psychological side effects, and don't address the underlying cause. Leuvas Therapeutics Inc. is targeting the biology of the disease with compounds that restore blood-brain barrier integrity and could treat all epilepsy patients without the side effects.
Leuvas co-founder and CEO Leslie McEvoy told BioCentury that